acetic acid-(3-benzyloxy-N-methyl-anilide) | 190070-39-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetic acid-(3-benzyloxy-N-methyl-anilide)
• 英文别名: Essigsaeure-(3-benzyloxy-N-methyl-anilid)；N-methyl-N-(3-phenylmethoxyphenyl)acetamide
• CAS: 190070-39-4
• 化学式: C₁₆H₁₇NO₂
• 分子量: 255.316
• InChiKey: DWQBZUPECLKGAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  acetic acid-(3-benzyloxy-N-methyl-anilide) 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 12.0h， 以91%的产率得到3-(苄氧基)-n-甲基苯胺
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists

  摘要：

  This paper describes the synthesis and pharmacological evaluation of three series of compounds 4a-b, 13a-k and 19, structurally related to the known potent cysLT(1) receptor antagonists RG-12553, ICI-204219 and ONO-1078, respectively. The common structural feature of these new series is the presence of a 4-quinolone nucleus acting as a template for substitution of the aromatic nucleus present in the prototype antagonists. We describe the evolution of these series leading to antagonists with potency at nanomolar concentrations in vitro.

  DOI：

  10.1016/s0223-5234(97)83282-5
• 作为产物：
  描述：

  3-(苄氧基)-n-甲基苯胺 生成 acetic acid-(3-benzyloxy-N-methyl-anilide)
  参考文献：
  名称：

  Morton; Slaunwhite, Journal of Biological Chemistry, 1949, vol. 179, p. 259,264

  摘要：

  DOI：

文献信息

• Morton; Slaunwhite, Journal of Biological Chemistry, 1949, vol. 179, p. 259,264
  作者：Morton、Slaunwhite

  DOI：——

  日期：——
• Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists
  作者：R Griera、M Armengol、A Reyes、M Alvarez、A Palomer、F Cabré、J Pascual、M.L. Garcia、D Mauleón

  DOI：10.1016/s0223-5234(97)83282-5

  日期：1997.7

  This paper describes the synthesis and pharmacological evaluation of three series of compounds 4a-b, 13a-k and 19, structurally related to the known potent cysLT(1) receptor antagonists RG-12553, ICI-204219 and ONO-1078, respectively. The common structural feature of these new series is the presence of a 4-quinolone nucleus acting as a template for substitution of the aromatic nucleus present in the prototype antagonists. We describe the evolution of these series leading to antagonists with potency at nanomolar concentrations in vitro.